Most Read

Said to be the first and only oral, once-a-day, 14-day treatment, ZURZUVAE can provide quick improvements in depressive symptoms for women with PPD. Shortly after scheduling as a

As per the terms of the exclusive worldwide agreement, Agios will acquire the rights to develop and market Alnylam’s preclinical candidate that targets TMPRSS6, a key driver of

The company received the patent from the European Patent Office. The drug is being assessed in the ongoing Phase III programme CONCLUDE for treating patients with moderate to

Co-led by Santé Ventures and Longwood, the financing round has seen participation from Alexandria Venture Investments, Astellas Venture Management, and DCVC Bio. Solu Therapeutics’ CyTaC platform has been

The drug-device combination product, Breyna is claimed to be the first US Food and Drug Administration (FDA)-approved generic version of AstraZeneca’s Symbicort. It will be immediately available in

RiVive is designed to provide access to naloxone without a prescription and is available as 3 mg naloxone hydrochloride nasal spray. This is the second over-the-counter product with

The first-in-class C5 complement inhibitor, Soliris has been indicated for anti-acetylcholine receptor antibody-positive children and adolescents aged six to 17 years. It is claimed to be the first

The start-up facilitates analytical and process development, CMC consulting as well as early-stage GMP manufacturing of cell therapies. Initially, its emphasis will be on manufacturing immune cell therapies, such

To be spread over a 69,000ft2 area, the expanded production unit will feature innovative technologies and equipment that aid in developing, producing and analysing advanced therapy medicinal products (ATMP). The